These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20970118)

  • 1. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.
    Bustillo JR; Chen H; Gasparovic C; Mullins P; Caprihan A; Qualls C; Apfeldorf W; Lauriello J; Posse S
    Biol Psychiatry; 2011 Jan; 69(1):19-27. PubMed ID: 20970118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.
    Bustillo JR; Jones T; Chen H; Lemke N; Abbott C; Qualls C; Stromberg S; Canive J; Gasparovic C
    Schizophr Bull; 2017 May; 43(3):611-619. PubMed ID: 27550776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.
    Plitman E; de la Fuente-Sandoval C; Reyes-Madrigal F; Chavez S; Gómez-Cruz G; León-Ortiz P; Graff-Guerrero A
    Schizophr Bull; 2016 Mar; 42(2):415-24. PubMed ID: 26320195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1H-MRS at 4 tesla in minimally treated early schizophrenia.
    Bustillo JR; Rowland LM; Mullins P; Jung R; Chen H; Qualls C; Hammond R; Brooks WM; Lauriello J
    Mol Psychiatry; 2010 Jun; 15(6):629-36. PubMed ID: 19918243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myoinositol and glutamate complex neurometabolite abnormality after mild traumatic brain injury.
    Kierans AS; Kirov II; Gonen O; Haemer G; Nisenbaum E; Babb JS; Grossman RI; Lui YW
    Neurology; 2014 Feb; 82(6):521-8. PubMed ID: 24401686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.
    Bustillo JR; Jones T; Qualls C; Chavez L; Lin D; Lenroot RK; Gasparovic C
    J Affect Disord; 2019 Mar; 246():745-753. PubMed ID: 30623820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton MRS in twin pairs discordant for schizophrenia.
    Lutkenhoff ES; van Erp TG; Thomas MA; Therman S; Manninen M; Huttunen MO; Kaprio J; Lönnqvist J; O'Neill J; Cannon TD
    Mol Psychiatry; 2010 Mar; 15(3):308-18. PubMed ID: 18645571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Spitzberg K; Kersting A; Arolt V; Heindel W; Pfleiderer B
    Schizophr Res; 2005 Mar; 73(2-3):153-7. PubMed ID: 15653258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR spectroscopic evaluation of N-acetylaspartate's T2 relaxation time and concentration corroborates white matter abnormalities in schizophrenia.
    Tunc-Skarka N; Weber-Fahr W; Hoerst M; Meyer-Lindenberg A; Zink M; Ende G
    Neuroimage; 2009 Nov; 48(3):525-31. PubMed ID: 19573608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction.
    Chang L; Friedman J; Ernst T; Zhong K; Tsopelas ND; Davis K
    Biol Psychiatry; 2007 Dec; 62(12):1396-404. PubMed ID: 17693392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
    Öngür D; Jensen JE; Prescot AP; Stork C; Lundy M; Cohen BM; Renshaw PF
    Biol Psychiatry; 2008 Oct; 64(8):718-726. PubMed ID: 18602089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical changes in welders revealed by proton magnetic resonance spectroscopy.
    Chang Y; Woo ST; Lee JJ; Song HJ; Lee HJ; Yoo DS; Kim SH; Lee H; Kwon YJ; Ahn HJ; Ahn JH; Park SJ; Weon YC; Chung IS; Jeong KS; Kim Y
    Neurotoxicology; 2009 Nov; 30(6):950-7. PubMed ID: 19631686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis.
    Sastre-Garriga J; Ingle GT; Chard DT; Ramió-Torrentà L; McLean MA; Miller DH; Thompson AJ
    Arch Neurol; 2005 Apr; 62(4):569-73. PubMed ID: 15824254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy.
    Tandon N; Bolo NR; Sanghavi K; Mathew IT; Francis AN; Stanley JA; Keshavan MS
    Schizophr Res; 2013 Aug; 148(1-3):59-66. PubMed ID: 23791389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect effects of elevated body mass index on memory performance through altered cerebral metabolite concentrations.
    Gonzales MM; Tarumi T; Eagan DE; Tanaka H; Vaghasia M; Haley AP
    Psychosom Med; 2012 Sep; 74(7):691-8. PubMed ID: 22822230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.
    Bustillo JR; Chen H; Jones T; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C
    JAMA Psychiatry; 2014 Mar; 71(3):265-72. PubMed ID: 24402128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.
    Natsubori T; Inoue H; Abe O; Takano Y; Iwashiro N; Aoki Y; Koike S; Yahata N; Katsura M; Gonoi W; Sasaki H; Takao H; Kasai K; Yamasue H
    Schizophr Bull; 2014 Sep; 40(5):1128-39. PubMed ID: 24023251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).
    Tayoshi S; Sumitani S; Taniguchi K; Shibuya-Tayoshi S; Numata S; Iga J; Nakataki M; Ueno S; Harada M; Ohmori T
    Schizophr Res; 2009 Mar; 108(1-3):69-77. PubMed ID: 19097753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoupling of N-acetyl-aspartate and glutamate within the dorsolateral prefrontal cortex in schizophrenia.
    Coughlin JM; Tanaka T; Marsman A; Wang H; Bonekamp S; Kim PK; Higgs C; Varvaris M; Edden RA; Pomper M; Schretlen D; Barker PB; Sawa A
    Curr Mol Med; 2015; 15(2):176-83. PubMed ID: 25732147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.